New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
07:56 EDTPFE, BAC, DTV, JPM, AZN, T, LAZLazard shares rise after AT&T mega-deal struck, WSJ says
Shares of Lazard (LAZ) rose yesterday after AT&T (T), which Lazard was the advisor for, announced its deal to acquire DirecTV (DTV), reported The Wall Street Journal. In contrast, JPMorgan (JPM), Bank of America (BAC) and Guggenheim Partners look set to be disappointed and lose out on potential fees as Pfizer's (PFE) bid for AstraZeneca (AZN) appears destined to fail, the report noted. The Journal added that the total value of agreed-upon U.S. deals is up 87% from last year to $585B year-to-date. Reference Link
News For LAZ;JPM;BAC;T;DTV;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 28, 2015
16:00 EDTBACOptions Update; September 28, 2015
Subscribe for More Information
15:01 EDTPFEPfizer volatility at high end of one-year range
Subscribe for More Information
07:52 EDTAZN, PFEIIR Holdings to hold a conference
Subscribe for More Information
07:28 EDTTSamsung to pay customers up to $120 for buying new Galaxy phone, Verge says
Samsung's (SSNLF) new promotion in the U.S. will pay the rest of a customer's monthly payments in 2015 towards a new Galaxy S6, S6 Edge, S6 Edge+, or Galaxy Note 5, the Verge reports. The promotion will result in $120 off the price of any of those phones if users buy one under a new carrier installment plan between now and October 9, the report says. AT&T (T) will sit the promotion out, the report says. Reference Link
07:27 EDTPFEFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
September 27, 2015
13:50 EDTBACBank of America likely to increase dividend, buyback plans, Barron's says
Subscribe for More Information
September 25, 2015
16:00 EDTPFE, BACOptions Update; September 25, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 25.09. Option volume leaders: AAPL NFLX BAC FB AU NKE PFE INTC AMZN TSLA
09:34 EDTPFE, BACActive equity options trading on open
Active equity options trading on open: AAPL BAC FB NKE NFLX PFE AU TSLA
07:22 EDTAZN, PFEEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
07:03 EDTPFEMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information
05:08 EDTPFEStocks with implied volatility movement; PFE HLF
Subscribe for More Information
September 24, 2015
17:04 EDTPFEMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
16:00 EDTBACOptions Update; September 24, 2015
Subscribe for More Information
09:22 EDTTSprint to offer iPhone 6s 16GB for $1 per month
Subscribe for More Information
07:33 EDTPFEBIND says Pfizer exercises option to obtain license for Accurin drug candidate
BIND Therapeutics (BIND) announced that Pfizer (PFE) exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement. The actively targeted Accurin is designed to impart cellular targeting capability and was engineered by BIND using one of Pfizer's proprietary kinase inhibitors and one of BIND's proprietary ligands. As a result of the option exercise, BIND will receive a $2.5 million option exercise fee from Pfizer. In parallel with exercising its first option, Pfizer informed BIND that it will not exercise its option for the second compound in the collaboration. Under terms of the original collaboration agreement, which was established in April 2013, Pfizer was granted options to obtain exclusive licenses to pursue development and commercialization of two Accurins that incorporate specified Pfizer small molecular targeted therapies. For the Accurin that has been selected, both companies will work together on preclinical research; Pfizer will have responsibility for development and commercialization, and BIND will conduct chemistry, manufacturing and control activities. In addition to the $2.5 million option exercise fee, BIND received an upfront payment of $4.0 million in 2013 and achieved a $1.0 million preclinical development milestone for the selected Accurin in December 2014. BIND has the potential to receive additional milestone payments for the selected Accurin of up to $86.0 million in aggregate upon the achievement of additional specified development and regulatory events under the Pfizer collaboration agreement. BIND may also receive additional milestone payments for the selected Accurin of up to $110 million in aggregate for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of the selected Accurin, if any.
07:10 EDTJPM, BACBanks clash with regulators over energy lending, WSJ reports
Banks are fighting with regulators over loan reviews that might compress the flow of net credit to the oil patch, the Wall Street Journal reports. The disagreement is focused on the narrow issue of loans secured by oil and gas companies' reserves, but it highlights the point of how postcrisis regulation of the financial industry impacts sectors outside of Wall Street, the report says. Caught in between banks and regulators are the small and medium exploration and production companies that rely on credit lines using their energy reserves as collateral, the report says. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
September 23, 2015
17:41 EDTTAT&T, CSC announce hybrid cloud management platform
Subscribe for More Information
16:00 EDTJPM, BACOptions Update; September 23, 2015
iPath S&P 500 VIX Short-Term Futures down 53c to 23.81 Option volume leaders: AAPL NFLX BAC FB BABA DOW RIG MU FCX PBR XOM JPM
11:48 EDTTSynchronoss drops after concerns raised about Verizon cloud business
After Verizon (VZ) recently reduced the amount of free cloud storage it provides to customers as part of its cost cutting efforts, analysts at Baird told investors they were "increasingly concerned" that the telecom giant is "no longer fully committed" to the white-label cloud product it offers via its agreement with cloud services provider Synchronoss Technologies (SNCR). Analysts at two other firms have issued defenses of Synchronoss in the wake of its sharp decline today. BEARISH VIEW: After Version cut its free cloud storage to 5GB from 25GB, Baird said it believed the Telco is less committed to Synchronoss' cloud offering, which the firm contended will "likely have revenue implications for 2016." The firm, which said it has had a negative bias on Synchronoss due to long-term cloud competitive concerns and the lack of growth outside of AT&T (T) and Verizon, has a Neutral rating on the cloud services provider's shares. DEFENSES: JPMorgan analyst Sterling Auty attributes today's pullback in shares of Synchronoss to the concerns raised about the potential loss of Verizon as a cloud customer. Auty, however, sees "no chance" of Synchronoss losing Verizon as a customer in the near-term since the wireless carrier recently renewed its contract with the company for multiple years. He views today's selloff as a "significant overreaction" and recommends buying Synchronoss at current levels. Also noting concerns raised about Synchronoss' potential loss of some cloud business, Wells Fargo said even if Synchronoss' cloud business exhibited zero growth in 2016 from 2015, shares would be compelling at current levels. The firm views the selloff as overdone and reiterates its Overweight rating on Synchronoss shares. PRICE ACTION: Synchronoss shares, which dipped as low as $27.86 this morning, are off their worst levels but remain down $4.65 to $32.74 in late morning trading.
05:32 EDTPFEViiV Healthcare announces Triumeq Phase IIIb study met primary endpoint
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use